BioReference Laboratories' OnkoSight

BioReference Laboratories has introduced two sequencing tests that it believes will enhance the information that physicians can obtain from tumor samples when treating oncology patients. The company will offer this next-generation sequencing program, called OnkoSight, through its GenPath Oncology business unit. The custom-designed NGS panels ar OnkoSight Solid, consisting of 31 genes for solid tumors; and OnkoSight Myeloid, comprising 37 genes for myeloid disorders. The company said that six additional focused panels are available based on tumor type: lung, colon, melanoma, myelodsyplastic syndromes, acute myeloid leukemia, and myeloproliferative neoplasms.